Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kristina Campton

Dermatology New York, NY Medical Doctor

NPI 1902832777 CMS profile 312739

115 E 57Th St Ste 400, New York, NY 10022

Open in the dashboard

General payments

$21,347

689 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$13,236 paid to institutions, not to them · program years 2020–2021

Through program year 2025, Kristina Campton of New York, NY is reported in the CMS Open Payments database as having received $21,347 across 689 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $13,236 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 89th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $8,161 293
2024 General $9,419 192
2023 General $2,052 102
2022 General $732 44
2021 General $223 11
2020 General $176 9
2019 General $584 38

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kristina Campton
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Kristina Campton were reported at $8,161. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Kristina Campton Dermatology median Middle half National median
2019 $584 $454 $129–$1,240 $163
2020 $176 $235 $81–$756 $114
2021 $223 $377 $108–$1,108 $132
2022 $732 $514 $143–$1,391 $149
2023 $2,052 $607 $159–$1,674 $160
2024 $9,419 $751 $204–$1,903 $164
2025 $8,161 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $6,846 67 payments
  2. AbbVie, Inc. $4,227 125 payments
  3. Incyte Corporation $3,512 109 payments
  4. UCB, Inc. $872 57 payments
  5. Sun Pharmaceutical Industries Inc. $774 44 payments
  6. Janssen Biotech, Inc. $762 38 payments
  7. Dermavant Sciences, Inc. $512 23 payments
  8. Novartis Pharmaceuticals Corporation $449 24 payments
  9. Galderma Laboratories, L.P. $364 30 payments
  10. Arcutis Biotherapeutics, Inc. $344 37 payments
  11. Other $2,684 135 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,290 681 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $5,040 1 payment
  3. Consulting Fee $3,977 2 payments
  4. Travel and Lodging $840 1 payment
  5. Education $200 4 payments
Products named General payments · program years 2019–2025
  1. CIBINQO $6,757 62 payments
  2. RINVOQ $3,180 73 payments
  3. OPZELURA $1,189 107 payments
  4. Bimzelx $845 56 payments
  5. Winlevi $763 43 payments
  6. TREMFYA $762 38 payments
  7. LITFULO $708 50 payments
  8. SKYRIZI $519 25 payments
  9. EUCRISA $400 27 payments
  10. VTAMA $385 23 payments
  11. Other $5,371 313 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 31 drugs

Part D claims

2,449

Median for Dermatology: 534

Drug cost

$2,226,502

Median for Dermatology: $67,151

Branded share of claims

35%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Opzelura Ruxolitinib Phosphate Brand 557 $1,085,410
Rinvoq Upadacitinib Brand 94 $626,123
Humira(Cf) Pen Adalimumab Brand 21 $247,746
Nuzyra Omadacycline Tosylate Brand 16 $121,527
Litfulo Ritlecitinib Tosylate Brand 11 $43,202
Vtama Tapinarof Brand 27 $36,986
Clobetasol Propionate Generic 318 $19,585
Winlevi Clascoterone Brand 22 $12,345
Triamcinolone Acetonide Generic 271 $5,205
Tretinoin Generic 61 $4,755

The 10 drugs with the highest cost, of 31 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 22 billing codes

Paid by Medicare

$38,960

Medicare's payments for the services billed

Medicare patients

203

Average age 74

Services billed

757

132 women, 71 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 48%
Diabetes 29%
Ischemic heart disease 28%
Depression 25%
Osteoporosis 23%
Chronic kidney disease 22%
Heart failure 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CIBINQO
$5,973 — —
RINVOQ
$492 94 —
Winlevi
$374 22 —
OPZELURA
$350 557 —
VTAMA
$313 27 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

689 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record